Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
Abstract Background Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore we aimed to use a blood-based protein sign...
Main Authors: | Bo Jia, Zhi Dong, Di Wu, Jun Zhao, Meina Wu, Tongtong An, Yuyan Wang, Minglei Zhuo, Jianjie Li, Yang Wang, Jie Zhang, Xinghui Zhao, Sheng Li, Junfeng Li, Menglei Ma, Chen Chen, Xue Yang, Jia Zhong, Hanxiao Chen, Jingjing Wang, Yujia Chi, Xiaoyu Zhai, Song Cui, Rong Zhang, Qingwei Ma, Jian Fang, Ziping Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-12-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-020-01662-5 |
Similar Items
-
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients
by: Mary Jo Fidler, et al.
Published: (2018-03-01) -
Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration
by: Olga Efimova, et al.
Published: (2017-05-01) -
ANALIZA STRAT WODY NA PRZYKŁADZIE WYBRANEGO WODOCIĄGU GRUPOWEGO
by: Anna MUSZ-POMORSKA, et al.
Published: (2016-03-01) -
A Case Report on Successful Third Challenge to the Pemetrexed-based Regimen for Advanced Non-small Cell Lung Cancer
by: Linlin CHENG, et al.
Published: (2019-06-01) -
Propozycja modyfikacji wariantuporównawczego rachunkuzysków i strat w zakresie pozycjizrównanych z przychodami
by: Arkadiusz Górski, et al.
Published: (2010-10-01)